185 related articles for article (PubMed ID: 12846810)
1. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma.
Bergsagel PL; Kuehl WM
Immunol Rev; 2003 Aug; 194():96-104. PubMed ID: 12846810
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.
Shaughnessy J; Gabrea A; Qi Y; Brents L; Zhan F; Tian E; Sawyer J; Barlogie B; Bergsagel PL; Kuehl M
Blood; 2001 Jul; 98(1):217-23. PubMed ID: 11418483
[TBL] [Abstract][Full Text] [Related]
3. Advances in biology of multiple myeloma: clinical applications.
Hideshima T; Bergsagel PL; Kuehl WM; Anderson KC
Blood; 2004 Aug; 104(3):607-18. PubMed ID: 15090448
[TBL] [Abstract][Full Text] [Related]
4. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
Bergsagel PL; Kuehl WM; Zhan F; Sawyer J; Barlogie B; Shaughnessy J
Blood; 2005 Jul; 106(1):296-303. PubMed ID: 15755896
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis and a consequent classification of multiple myeloma.
Bergsagel PL; Kuehl WM
J Clin Oncol; 2005 Sep; 23(26):6333-8. PubMed ID: 16155016
[TBL] [Abstract][Full Text] [Related]
6. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma.
Chesi M; Kuehl WM; Bergsagel PL
Ann Oncol; 2000; 11 Suppl 1():131-5. PubMed ID: 10707795
[TBL] [Abstract][Full Text] [Related]
7. Chromosome translocations in multiple myeloma.
Bergsagel PL; Kuehl WM
Oncogene; 2001 Sep; 20(40):5611-22. PubMed ID: 11607813
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing primary and secondary translocations in multiple myeloma.
Gabrea A; Leif Bergsagel P; Michael Kuehl W
DNA Repair (Amst); 2006 Sep; 5(9-10):1225-33. PubMed ID: 16829212
[TBL] [Abstract][Full Text] [Related]
9. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.
Glassford J; Rabin N; Lam EW; Yong KL
Br J Haematol; 2007 Oct; 139(2):243-54. PubMed ID: 17897300
[TBL] [Abstract][Full Text] [Related]
10. New insights into the pathophysiology of multiple myeloma.
Seidl S; Kaufmann H; Drach J
Lancet Oncol; 2003 Sep; 4(9):557-64. PubMed ID: 12965277
[TBL] [Abstract][Full Text] [Related]
11. Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.
Fabris S; Agnelli L; Mattioli M; Baldini L; Ronchetti D; Morabito F; Verdelli D; Nobili L; Intini D; Callea V; Stelitano C; Lombardi L; Neri A
Genes Chromosomes Cancer; 2005 Feb; 42(2):117-27. PubMed ID: 15543617
[TBL] [Abstract][Full Text] [Related]
12. Early genetic events provide the basis for a clinical classification of multiple myeloma.
Kuehl WM; Bergsagel PL
Hematology Am Soc Hematol Educ Program; 2005; ():346-52. PubMed ID: 16304402
[TBL] [Abstract][Full Text] [Related]
13. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.
Rasmussen T; Theilgaard-Mönch K; Hudlebusch HR; Lodahl M; Johnsen HE; Dahl IM
Br J Haematol; 2003 Oct; 123(2):253-62. PubMed ID: 14531906
[TBL] [Abstract][Full Text] [Related]
14. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
Maxwell CA; Pilarski LM
Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
[TBL] [Abstract][Full Text] [Related]
15. Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF.
Takimoto M; Ogawa K; Kato Y; Saito T; Suzuki T; Irei M; Shibuya Y; Suzuki Y; Kato M; Inoue Y; Takahashi M; Sugimori H; Miura I
Int J Hematol; 2008 Apr; 87(3):260-5. PubMed ID: 18274833
[TBL] [Abstract][Full Text] [Related]
16. IgH translocations in multiple myeloma: a nearly universal event that rarely involves c-myc.
Bergsagel PL; Nardini E; Brents L; Chesi M; Kuehl WM
Curr Top Microbiol Immunol; 1997; 224():283-7. PubMed ID: 9308253
[TBL] [Abstract][Full Text] [Related]
17. [Molecular Mechanism and Malignant Clonal Evolution of Multiple Myeloma].
Ding F; Zhu P; Wu XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1513-6. PubMed ID: 26524068
[TBL] [Abstract][Full Text] [Related]
18. Advances in biology and therapy of multiple myeloma.
Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.
Sáez B; Martín-Subero JI; Lahortiga I; Largo C; Larrayoz MJ; Odero MD; Prosper F; Cigudosa JC; Siebert R; Calasanz MJ
Cancer Genet Cytogenet; 2007 May; 175(1):65-8. PubMed ID: 17498561
[TBL] [Abstract][Full Text] [Related]
20. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
